Compare INTZ & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INTZ | NXTC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 17.3M |
| IPO Year | 2020 | 2019 |
| Metric | INTZ | NXTC |
|---|---|---|
| Price | $0.69 | $5.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.75 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 128.8K | 108.0K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.78 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,015,000.00 | ★ $22,378,000.00 |
| Revenue This Year | $25.34 | N/A |
| Revenue Next Year | $14.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.56 | N/A |
| 52 Week Low | $0.59 | $1.55 |
| 52 Week High | $2.27 | $15.74 |
| Indicator | INTZ | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 41.20 |
| Support Level | $0.67 | $3.98 |
| Resistance Level | $0.89 | $8.68 |
| Average True Range (ATR) | 0.07 | 0.78 |
| MACD | -0.01 | -0.23 |
| Stochastic Oscillator | 21.54 | 14.25 |
Intrusion Inc is a cybersecurity company based in Plano, Texas. The company offers its customers access to its exclusive threat intelligence database containing the historical data, known associations, and reputational behavior of Internet Protocol addresses. Its platform combines threat intelligence, malicious traffic identification, and automated threat response, and is designed to help organizations proactively identify and stop malicious activity in their networks. Its solutions include INTRUSION Shield, INTRUSION TraceCop, and INTRUSION Savant. The company operates in single segment.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.